Department of Veterinary Medicine, University of Cambridge, Madingley Road, Cambridge, CB3 0ES, UK.
Future Med Chem. 2014 Jan;6(1):45-55. doi: 10.4155/fmc.13.192.
Helicase-primase inhibitors (HPIs) are the first new family of potent herpes virus (herpes simplex and varicella-zoster virus) inhibitors to go beyond the preliminary stages of investigation since the emergence of the original nucleoside analog inhibitors. To consider the clinical future of HPIs, this review puts the exciting new findings with two HPIs, amenamevir and pritelivir, into the historical context of antiviral development for the prevention and treatment of herpes simplex virus over the last century and, on this basis, the authors speculate on the potential evolution of these and other non-nucleoside inhibitors in the future.
解旋酶-引发酶抑制剂（HPIs）是自最初的核苷类似物抑制剂出现以来，第一个超越研究初步阶段的新型有效疱疹病毒（单纯疱疹和水痘带状疱疹病毒）抑制剂家族。为了考虑 HPIs 的临床未来，本综述将两种 HPIs（amenamevir 和 pritelivir）的令人兴奋的新发现置于过去一个世纪预防和治疗单纯疱疹病毒的抗病毒药物开发的历史背景下，并在此基础上推测这些和其他非核苷抑制剂在未来的潜在发展。
